Food and Drug Administration
Center for Biologics
Evaluation and Research
SUMMARY MINUTES
VACCINES AND RELATED
BIOLOGICAL PRODUCTS ADVISORY COMMITTEE
Meeting # 89: January 30, 2002
Holiday Inn, Bethesda
Bethesda, Maryland
Committee
Members
Dr.
Robert Daum, Chair
Dr.
Pamela Diaz
Dr.
Walter Faggett
Ms.
Barbara Loe Fisher*
Dr.
Judith Goldberg
Dr.
Diane Griffin
Dr.
Sam Katz
Dr.
Kwang Sik Kim
Dr.
Steve Kohl
Dr.
Audrey Manley
Dr.
Peter Palese
Dr.
Dixie Snider
Dr.
David Stephens
Dr.
Rich Whitley
Committee
Members Absent
Dr.
Julie Parsonnet
Dr.
Robert Couch
Dr.
Walter Dowdle
Dr.
Theodore Eickhoff
Dr.
Martin Myers
Dr.
Gregory Poland
Guests/Guest
Speakers
Ms.
Linda Canas
Dr.
Nancy Cox
Col.
Benedict Diniega
Dr.
Keiji Fukuda
Dr.
Gregory Slusaw
Dr.
Zhiping Ye
Acting
Executive Secretary
Dr.
William Freas
These
summary minutes for the January 30, 2002 meeting of the Vaccines and Related
Biological Products Advisory Committee were approved on ______________________
.
I
certify that I attended the January 30, 2002 meeting of the Vaccines and
Related Biological Products Advisory Committee and that these minutes
accurately reflect what transpired.
_____________________________
______________________________
William
Freas, Ph.D. Robert S. Daum, M.D.
Executive
Secretary Chair
*Consumer
Representative
+Non-Voting
Industry Representative
The
89th meeting of the Vaccines and Related Biological Products
Advisory Committee was called to order at 9:00 a.m. on January 30, 2002 by the
Chair, Dr. Robert Daum. The meeting
addressed a single topic: selection of strains to be included in next year’s
2002-2003 influenza virus vaccine. The
entire meeting was held in open session.
CBER Director Dr. Kathryn Zoon presented plaques and certificates of appreciation to Drs. Kwang Sik Kim, Steve Kohl, and Dixie Snider whose terms on the committee were ending. Dr. Robert Daum will remain on the committee as Chair for an additional year.
Two Open Public Hearing sessions were announced. No public comment was offered at either session.
Following is a summary of the discussion. Additional information and specific details may be obtained from the transcript of the meeting. The transcript may be viewed on the world wide web at: http://www.fda.gov/ohrms/dockets/ac/02acsdocs.htm. A copy of the agenda is attached.
Proceedings
were adjourned at approximately 4:00 p.m. on January 30, 2002.
Session #1 – Open Session
Strain Selection for
Influenza Virus Vaccine for the 2002-2003 Season
The panel heard presentations on strains of circulating influenza virus. After discussion, the committee made the following recommendations for the influenza virus strains to be included in vaccine for use during the 2002-2003 season in the United States.
Based
on information about the appearance and epidemiology of new influenza virus
variants, responses to current vaccines and the availability of strains and
reagents needed for manufacturing, the committee recommended a trivalent
formulation.
·
The
committee recommended that for the influenza A H1N1 component, A/New
Caledonia/20/99, should be retained.
·
Based
on current information, the committee also recommended that the influenza A
H3N2 component, A/Panama/2007/99 (an A/Moscow/10/99-like strain), should be
retained unless new information obtained in the next few weeks suggests that
another strain might be a better match with naturally circulating viruses.
·
The
committee also recommended deferring the decision regarding the influenza B
virus component. It is very early in the influenza season epidemic and in the
data collection to determine if the influenza B component should be changed
from the current strain. The committee
felt that it was too early to identify a B virus suitable to support
large-scale manufacturing. The committee discussed retaining the current
B/Sichuan/379/99-like virus; and adding to, in addition, the
B/Victoria/504/2000-like virus strain as a possible candidate if it has the
needed characteristics for large-scale production
·
The
committee strongly recommended that strain surveillance data be
obtained from a
pediatric population to study pediatric immunigenicity and efficacy of the
influenza vaccine, as this group is relatively unprimed
and may display a distinct pattern of susceptibility to the circulating strains
compared to the adult population.